Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Nursing | Pediatrics | Journal

Back to Journal Articles

HPV Vaccination Doesn’t Up Poor Outcomes for Sexual Activity

Last Updated: October 15, 2012.

 

Receipt of vaccine at age 11 to 12 doesn't correlate with increase in pregnancy/STI testing, diagnosis

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For girls, receipt of human papillomavirus vaccination at the recommended ages (11 to 12 years) does not correlate with an increase in sexual activity-related outcomes, according to a study published online Oct. 15 in Pediatrics.

MONDAY, Oct. 15 (HealthDay News) -- For girls, receipt of human papillomavirus (HPV) vaccination at the recommended ages (11 to 12 years) does not correlate with an increase in sexual activity-related outcomes, according to a study published online Oct. 15 in Pediatrics.

Robert A. Bednarczyk, Ph.D., from Kaiser Permanente in Atlanta, and colleagues examined sexual activity-related clinical outcomes after HPV vaccination in a cohort of 1,398 11- to 12-year-old girls, of whom 493 were exposed to the HPV vaccine and 905 were not. Outcomes were assessed during up to three years of follow-up.

The researchers found that there was no significant increase in the risk of the composite primary outcome (any pregnancy/sexually transmitted infection testing or diagnosis or contraceptive counseling) in HPV vaccine-exposed versus unexposed girls (rate ratio, 1.29; 95 percent confidence interval, 0.92 to 1.80). There were also no clinically significant differences in absolute risk for Chlamydia infection or pregnancy diagnoses for exposed versus unexposed girls.

"Receipt of HPV vaccine by 11- to 12-year-old girls was not associated with clinical markers of increased sexual activity-related outcomes, such as sexually transmitted diseases or pregnancy," Bednarczyk and colleagues conclude.

Several authors or their institutions disclosed financial ties to Merck and Roche.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Abraxane Approved to Treat Advanced Lung Cancer Next: Even Modest Sleep Increase Improves Child Behavior

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.